Sato H, Albrecht P, Krugman S, Ennis F A
J Clin Microbiol. 1979 Feb;9(2):259-65. doi: 10.1128/jcm.9.2.259-265.1979.
A modified rubella virus plaque neutralization test for measuring rubella antibody was developed based on the potentiation of the virus-antibody complex by heterologous anti-immunoglobulin. The test is highly sensitive, yielding titers on the average 50 to 100 times higher than the haemagglutination inhibition test or the conventional plaque neutralization test. The sensitivity of this enhanced neutralization test is somewhat limited by the existence of a prozone phenomenon which precludes testing of low-titered sera below a dilution of 1:16. No prozone effect was observed with cerebrospinal fluids. The specificity of the enhanced neutralization test was determined by seroconversion of individuals receiving rubella vaccine. Although the rubella hemagglutination inhibition test remains the test of choice in routine diagnostic and surveillance work, the enhanced rubella neutralization test is particularly useful in monitoring low-level antibody in the cerebrospinal fluid in patients with neurological disorders and in certain instances of vaccine failure.
基于异源抗免疫球蛋白对病毒 - 抗体复合物的增强作用,开发了一种用于测量风疹抗体的改良风疹病毒空斑中和试验。该试验高度灵敏,其效价平均比血凝抑制试验或传统空斑中和试验高50至100倍。这种增强中和试验的灵敏度在一定程度上受到前带现象的限制,该现象使得无法检测稀释度低于1:16的低滴度血清。脑脊液未观察到前带效应。通过接受风疹疫苗个体的血清转化来确定增强中和试验的特异性。尽管风疹血凝抑制试验仍是常规诊断和监测工作中的首选试验,但增强风疹中和试验在监测神经系统疾病患者脑脊液中的低水平抗体以及某些疫苗接种失败的情况下特别有用。